- \n
- \n
Achieved record annual sales exceeding $1 billion for the first time, supported by year-over-year growth across all three reporting segments.<\/p>\n<\/li>\n
- \n
Attributed strong Human Nutrition and Health performance to the ‘better-for-you’ consumer shift toward nutrient-dense, high-protein, and low-sugar food formulations.<\/p>\n<\/li>\n
- \n
Mitigated global trade and tariff volatility through a localized manufacturing model where approximately 85% of products are sold in the region of production.<\/p>\n<\/li>\n
- \n
Expanded international market presence significantly, with more than half of the company’s 2025 sales growth originating from markets outside the United States.<\/p>\n<\/li>\n
- \n
Leveraged strategic marketing partnerships with the New York Jets and Bayern Munich to reposition choline and K2 vitamins for adult cognition and women’s health.<\/p>\n<\/li>\n
- \n
Maintained operational consistency marking the 26th consecutive quarter of year-over-year adjusted EBITDA growth through disciplined execution.<\/p>\n<\/li>\n
- \n
Advanced sustainability initiatives, surpassing the 2030 greenhouse gas emission reduction goal early with a 31% reduction against the 2020 baseline.<\/p>\n<\/li>\n<\/ul>\n
- \n
- \n
Commenced construction of a state-of-the-art microencapsulation facility in New York to support future growth in food ingredients and nutraceuticals.<\/p>\n<\/li>\n
- \n
Anticipates results from over 20 active clinical studies in 2026, including high-dose choline research potentially linked to adult cognition and Alzheimer’s delay.<\/p>\n<\/li>\n
- \n
Plans to launch a ‘beauty-from-within’ marketing campaign for MSM, targeting the growing consumer trend in skin, hair, and nail health supplements.<\/p>\n<\/li>\n
- \n
Expects continued recovery in the European monogastric market following the finalization of antidumping duties on Chinese choline in late December 2025.<\/p>\n<\/li>\n
- \n
Maintains a capital allocation strategy prioritizing organic growth and strategic M&A, supported by a low net debt leverage ratio of 0.3.<\/p>\n<\/li>\n<\/ul>\n
- \n
- \n
Navigated a theoretical $20 million tariff impact, successfully reducing the actual effect to approximately $10 million through supply chain diversification.<\/p>\n<\/li>\n
- \n
Reported a 40 basis point decline in gross margin percentage primarily due to higher manufacturing input costs during the fourth quarter.<\/p>\n<\/li>\n
- \n
Increased the annual dividend by 10% to $0.96 per share, representing the 17th consecutive year of double-digit dividend growth.<\/p>\n<\/li>\n
- \n
Executed a share repurchase program of approximately 685,000 shares to offset equity incentive dilution and return capital to shareholders.<\/p>\n<\/li>\n<\/ul>\n
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 pick. Tap here.<\/strong><\/em><\/p>\n<\/p><\/div>\n
- \n
- \n